Hillstream Biopharma (CNTN) Competitors $3.52 +0.17 (+5.07%) Closing price 04:00 PM EasternExtended Trading$3.52 0.00 (0.00%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock CNTN vs. PHAT, PHAR, ETON, SDGR, and MGTXShould you buy Hillstream Biopharma stock or one of its competitors? MarketBeat compares Hillstream Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hillstream Biopharma include Phathom Pharmaceuticals (PHAT), Pharming Group (PHAR), Eton Pharmaceuticals (ETON), Schrodinger (SDGR), and MeiraGTx (MGTX). These companies are all part of the "pharmaceutical products" industry. CNTN vs. PHATCNTN vs. PHARCNTN vs. ETONCNTN vs. SDGRCNTN vs. MGTXHow does Hillstream Biopharma compare to Phathom Pharmaceuticals?Phathom Pharmaceuticals (NASDAQ:PHAT) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Is PHAT or CNTN more profitable? Hillstream Biopharma has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Hillstream Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-76.77% N/A -44.29% Hillstream Biopharma N/A -31.50%-24.72% Does the media favor PHAT or CNTN? In the previous week, Hillstream Biopharma had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 5 mentions for Hillstream Biopharma and 4 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.40 beat Hillstream Biopharma's score of -0.14 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, PHAT or CNTN? Phathom Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Which has preferable earnings and valuation, PHAT or CNTN? Hillstream Biopharma has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$175.11M5.14-$221.25M-$2.12N/AHillstream BiopharmaN/AN/A-$35.92M-$1.15N/A Do institutionals & insiders have more ownership in PHAT or CNTN? 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 6.7% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend PHAT or CNTN? Phathom Pharmaceuticals currently has a consensus price target of $25.00, suggesting a potential upside of 121.34%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than Hillstream Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryPhathom Pharmaceuticals beats Hillstream Biopharma on 9 of the 16 factors compared between the two stocks.How does Hillstream Biopharma compare to Pharming Group?Pharming Group (NASDAQ:PHAR) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability. Do analysts prefer PHAR or CNTN? Pharming Group presently has a consensus price target of $38.33, suggesting a potential upside of 199.95%. Given Pharming Group's stronger consensus rating and higher probable upside, research analysts plainly believe Pharming Group is more favorable than Hillstream Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharming Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk & volatility, PHAR or CNTN? Pharming Group has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Which has preferable valuation and earnings, PHAR or CNTN? Pharming Group has higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharming Group$369.49M2.44$2.85M$0.1679.88Hillstream BiopharmaN/AN/A-$35.92M-$1.15N/A Is PHAR or CNTN more profitable? Pharming Group has a net margin of 3.30% compared to Hillstream Biopharma's net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Hillstream Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Pharming Group3.30% 4.64% 2.55% Hillstream Biopharma N/A -31.50%-24.72% Does the media favor PHAR or CNTN? In the previous week, Hillstream Biopharma had 5 more articles in the media than Pharming Group. MarketBeat recorded 5 mentions for Hillstream Biopharma and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.00 beat Hillstream Biopharma's score of -0.14 indicating that Pharming Group is being referred to more favorably in the media. Company Overall Sentiment Pharming Group Neutral Hillstream Biopharma Neutral Do insiders & institutionals believe in PHAR or CNTN? 0.0% of Pharming Group shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 6.7% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryPharming Group beats Hillstream Biopharma on 11 of the 15 factors compared between the two stocks.How does Hillstream Biopharma compare to Eton Pharmaceuticals?Hillstream Biopharma (NASDAQ:CNTN) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Do analysts rate CNTN or ETON? Eton Pharmaceuticals has a consensus price target of $41.00, suggesting a potential upside of 25.40%. Given Eton Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eton Pharmaceuticals is more favorable than Hillstream Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Eton Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Do insiders and institutionals hold more shares of CNTN or ETON? 1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 6.7% of Hillstream Biopharma shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, CNTN or ETON? Hillstream Biopharma has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Is CNTN or ETON more profitable? Hillstream Biopharma has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Hillstream Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Hillstream BiopharmaN/A -31.50% -24.72% Eton Pharmaceuticals -1.70%-5.68%-1.49% Does the media prefer CNTN or ETON? In the previous week, Hillstream Biopharma and Hillstream Biopharma both had 5 articles in the media. Eton Pharmaceuticals' average media sentiment score of -0.12 beat Hillstream Biopharma's score of -0.14 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, CNTN or ETON? Eton Pharmaceuticals has higher revenue and earnings than Hillstream Biopharma. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHillstream BiopharmaN/AN/A-$35.92M-$1.15N/AEton Pharmaceuticals$79.95M11.20-$4.60M-$0.07N/A SummaryEton Pharmaceuticals beats Hillstream Biopharma on 11 of the 14 factors compared between the two stocks.How does Hillstream Biopharma compare to Schrodinger?Schrodinger (NASDAQ:SDGR) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Does the media favor SDGR or CNTN? In the previous week, Schrodinger and Schrodinger both had 5 articles in the media. Schrodinger's average media sentiment score of -0.13 beat Hillstream Biopharma's score of -0.14 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is SDGR or CNTN more profitable? Hillstream Biopharma has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Hillstream Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Schrodinger-40.61% -30.85% -15.32% Hillstream Biopharma N/A -31.50%-24.72% Which has better valuation & earnings, SDGR or CNTN? Hillstream Biopharma has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSchrodinger$255.87M3.85-$103.26M-$1.41N/AHillstream BiopharmaN/AN/A-$35.92M-$1.15N/A Which has more volatility and risk, SDGR or CNTN? Schrodinger has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market. Do analysts rate SDGR or CNTN? Schrodinger presently has a consensus target price of $20.25, suggesting a potential upside of 51.89%. Given Schrodinger's stronger consensus rating and higher possible upside, analysts clearly believe Schrodinger is more favorable than Hillstream Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do institutionals & insiders believe in SDGR or CNTN? 79.1% of Schrodinger shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 10.1% of Schrodinger shares are held by company insiders. Comparatively, 6.7% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummarySchrodinger beats Hillstream Biopharma on 10 of the 14 factors compared between the two stocks.How does Hillstream Biopharma compare to MeiraGTx?Hillstream Biopharma (NASDAQ:CNTN) and MeiraGTx (NASDAQ:MGTX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations. Do insiders & institutionals believe in CNTN or MGTX? 1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 6.7% of Hillstream Biopharma shares are held by company insiders. Comparatively, 7.5% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation and earnings, CNTN or MGTX? Hillstream Biopharma has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHillstream BiopharmaN/AN/A-$35.92M-$1.15N/AMeiraGTx$81.39M10.50-$114.20M-$1.48N/A Do analysts rate CNTN or MGTX? MeiraGTx has a consensus target price of $25.83, indicating a potential upside of 179.88%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts clearly believe MeiraGTx is more favorable than Hillstream Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00MeiraGTx 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has more risk & volatility, CNTN or MGTX? Hillstream Biopharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Does the media prefer CNTN or MGTX? In the previous week, Hillstream Biopharma had 1 more articles in the media than MeiraGTx. MarketBeat recorded 5 mentions for Hillstream Biopharma and 4 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.35 beat Hillstream Biopharma's score of -0.14 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CNTN or MGTX more profitable? Hillstream Biopharma has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Hillstream Biopharma's return on equity of -31.50% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets Hillstream BiopharmaN/A -31.50% -24.72% MeiraGTx -151.12%-1,065.47%-54.96% SummaryHillstream Biopharma and MeiraGTx tied by winning 8 of the 16 factors compared between the two stocks. Get Hillstream Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTN vs. The Competition ExportMetricHillstream BiopharmaPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$247.46M$900.73M$4.24B$12.33BDividend YieldN/A4.84%6.21%5.33%P/E Ratio-3.081.4522.0425.75Price / SalesN/A117.31122.4898.92Price / CashN/A20.0753.8556.16Price / Book0.537.5634.777.03Net Income-$35.92M-$3.91M$112.32M$335.04M7 Day Performance-2.07%1.26%1.77%2.72%1 Month Performance-0.14%74.27%2.83%1.53%1 Year PerformanceN/A121.05%16.14%35.73% Hillstream Biopharma Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTNHillstream Biopharma0.6535 of 5 stars$3.52+5.1%N/AN/A$245.71MN/AN/A2PHATPhathom Pharmaceuticals2.5037 of 5 stars$11.40+0.1%$25.00+119.3%+196.9%$908.42M$175.11MN/A110PHARPharming Group3.4505 of 5 stars$12.62flat$38.33+203.8%+22.1%$891.29M$376.13M78.88280ETONEton Pharmaceuticals3.9548 of 5 stars$32.89+1.2%$41.00+24.7%+72.9%$889.98M$79.95MN/A20SDGRSchrodinger2.866 of 5 stars$11.99-0.5%$20.25+68.9%-35.5%$889.59M$255.87MN/A790 Related Companies and Tools Related Companies Phathom Pharmaceuticals Competitors Pharming Group Competitors Eton Pharmaceuticals Competitors Schrodinger Competitors MeiraGTx Competitors Janux Therapeutics Competitors Sana Biotechnology Competitors Theravance Biopharma Competitors Arbutus Biopharma Competitors Oric Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTN) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hillstream Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
